Evolution of oncolytic adenovirus for cancer treatment

Area of Science:

• Oncolytic virotherapy
• Cancer gene therapy
• Adenovirus-based therapeutics

Background:

• Oncolytic adenoviruses (Ads) show promise in cancer gene therapy due to selective tumor cell infection and replication.
• Current limitations in oncolytic Ad efficacy necessitate strategies for enhanced antitumor activity.
• Improving systemic delivery and tumor targeting are crucial for effective Ad-based cancer treatment.

Purpose of the Study:

• To review updated strategies for developing potent oncolytic adenoviruses for cancer treatment.
• To highlight advancements in enhancing the therapeutic efficacy of oncolytic Ads.
• To discuss methods for improving systemic delivery and tumor targeting of oncolytic Ads.

Main Methods:

• Development of single-vector Ads armed with therapeutic payloads (e.g., short hairpin RNA, cytokines).
• Modification of Ad surfaces with polymers, liposomes, or nanoparticles for improved pharmacokinetics and reduced immunogenicity.
• Engineering of Ad targeting platforms for enhanced tumor selectivity.

Main Results:

• Armed Ads demonstrate viral amplification of therapeutic genes and additive antitumor effects.
• Surface modifications extend circulation time, reduce liver accumulation and toxicity, and enhance antitumor effects.
• Targeting platforms facilitate tumor-specific oncolytic therapies for primary and metastatic cancers.

Conclusions:

• Oncolytic Ads can be significantly enhanced through genetic engineering and surface modification.
• These strategies improve systemic delivery, tumor targeting, and overall therapeutic efficacy.
• Advanced oncolytic adenovirus strategies hold significant potential for improved cancer treatment outcomes.